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SUMMARY
Trans-oral robotic surgery (TORS) has changed surgical management of patients with oropharyngeal squamous cell carcinomas (OPSCC). 
In this study we present surgical and oncologic outcomes of patients with oropharyngeal squamous cell carcinomas, treated using TORS, 
with and without an adjuvant therapy. Sixty patients with oropharyngeal squamous cell carcinomas treated with TORS between January 
2008 and December 2017 have been retrospectively evaluated considering clinicopathologic features, disease characteristics, adjuvant 
treatments and oncological outcomes. TORS was performed for OPSCC to the base of tongue in 41.7%, tonsils in 46.7%, soft palate and 
posterior pharyngeal wall in 3.3% and 5%, respectively. Neck dissection was performed in 43.3% of patients. Management strategies 
included surgery alone in 30%, TORS and adjuvant radiotherapy in 33.3%, and TORS plus adjuvant chemotherapy in 36.7%. The 5-year 
overall survival of the total group was 77.6%, the 5-year disease-free survival rate was 85.2%, and the 5-year local recurrence-free survival 
rate was 90.6%. Finally, in selected patients TORS appears to yield similar oncologic outcomes and functional outcomes to traditional 
techniques and non-operative treatment with a possible benefit on long-term quality of life. The future offers exciting opportunities to com-
bine TORS and radiotherapy in unique ways. However, further research is urgently needed to clarify the indications for adjuvant therapy 
following TORS resections.
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RIASSUNTO 
Nell’ultimo decennio, la chirurgia robotica trans-orale (TORS) ha rivoluzionato la gestione chirurgica dei pazienti con carcinoma 
dell’orofaringe(OPSCC). Questo studio monocentrico presenta i risultati oncologici delle neoplasie orofaringee trattate con TORS con 
e senza terapia adiuvante nei primi nove anni della nostra esperienza robotica. Sessanta pazienti sono stati trattati tra gennaio 2008 e 
dicembre 2017. Sono stati acquisiti i dati riguardanti le caratteristiche clinico-patologiche, i trattamenti adiuvanti e gli esiti oncologici. 
La TORS è stata eseguita per OPSCC della base della lingua nel 41,7% dei casi; nel 46,7% per carcinoma tonsillare, mentre neoplasie del 
palato molle e/o della parete posteriore faringea  sono state rispettivamente il 3,3% e 5% dei casi. La svuotamento del collo è stato eseguito 
nel 43,3% dei pazienti. Le strategie di gestione includevano la sola chirurgia nel 30% dei casi, TORS e radioterapia adiuvante nel 33,3% 
e TORS e  radiochemioterapia adiuvante nel 36,7%. La sopravvivenza globale a 5 anni del gruppo totale è del 77,6%, il tasso di sopravvi-
venza libera da malattia a 5 anni è dell’85,2% e il tasso di sopravvivenza libera da recidiva locale a 5 anni è del 90,6%. Infine, in alcuni 
pazienti selezionati, la TORS sembra fornire esiti oncologici e funzionali simili alle tecniche tradizionali e al trattamento di preservazione 
d’organo con un possibile beneficio per la qualità della vita a lungo termine. Tuttavia, ulteriori ricerche sono urgentemente necessarie per 
chiarire le indicazioni e l’erogazione della terapia adiuvante dopo le resezioni TORS.
PAROLE CHIAVE: Chirurgia robotica • Orofaringeo • Cancro • Collo • HPV • p16 • Radioterapia • Chemioterapia
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Introduction
Over the past 40 years, non-operative management has 
become the most common therapy for oropharyngeal 
squamous cell carcinomas (OPSCC) due to advances in 
radiotherapy and the significant functional deficits left by 
traditional surgical approaches. On the other hand, the in-
troduction of trans-oral robotic surgery (TORS) has led to 
a resurgence in the role of surgery in the management of 
patients with OPSCC. The oncologic efficacy of TORS is 
clear and for selected patients, functional outcomes are 
outstanding 1. The goal of any oncological therapy should 
be to achieve long-term disease-free survival while mini-
mising acute and late toxicities. With modern radiother-
apy techniques, severe late toxicity is often minimal  2. 
Therefore, the decision to pursue an operative versus 
non-operative strategy is centred on patient and tumour 
factors identified on history, physical exam and imaging. 
One of the goals of a TORS resection is to obtain negative 
margins on the primary tumour with minimal functional 
morbidity. This issue is most achieved in early OPSCC, 
clearly localised in an oropharyngeal subsite. Effectively, 
TORS was approved by the United States Food and Drug 
Administration for benign and malignant tumours classi-
fied as T1-2 in 2009 3. Nevertheless, the use of TORS for 
select locoregionally advanced patients (cT3 or cN2-3) 
may improve oncologic control compared to chemoradia-
tion (CRT) alone 1. NCCN guidelines recognise transoral 
surgery as a potentially useful tool in the treatment of 
these selected patients 1. In addition, TORS may be a val-
uable method of de-intensification for the locoregionally-
advanced patient in at least three ways: decreasing the 
dose of radiotherapy (RT); obviating the need for chemo-
therapy and decreasing the radiotherapy target volume.
Herein, we specifically investigate our experience in treat-
ing OPSCC patients with TORS. 
Materials and methods
The medical charts of consecutive patients who underwent 
TORS for OPSCC at our Department between January 
2008 and December 2017 were evaluated retrospectively. 
Clinicopathologic features of interest included age at sur-
gery, comorbidity, sex, HPV status, final margin status, 
pathologic T classification, pathologic N classification, 
overall American Joint Committee on Cancer (AJCC) 
stage (7th edition), extracapsular spread (ECS) and pri-
mary treatment, including TORS alone, TORS and RT, 
and TORS and CRT. Tumour HPV status was considered 
positive if either HPV in situ hybridisation or HPV p16 
was positive. Exclusion criteria included distant metasta-
ses at presentation, primary treatment other than intent-
to-cure, or a history of previously treated head and neck 
squamous cell carcinoma. The surgical approach has pre-
viously been described 4 5. Of note, narrow band imaging 
(NBI) was used intraoperatively after 2010 to enhance re-
section of margins 4. The edges of surgical excision were 
set at least 1 cm from the tumour. Negative margins or 
close margins were stated if more than 5 mm or less than 
5 mm of surrounding free tissue was present on micro-
scopic evaluation, respectively. Adjuvant RT was recom-
mended for patients with N2b/N2c/N3 disease, close final 
margins, and all patients with T3 tumours. Adjuvant CRT 
was recommended for patients with pathologic ECS and 
positive margins. Recurrence was classified as the time 
between surgical treatment and the date at which a patient 
was diagnosed with a local recurrence, nodal recurrence, 
or distant metastases. A second primary tumour was de-
fined as occurring > 5 years after initial treatment or oc-
curring in a unique subsite separate from the original tu-
mour bed. Additionally, a re-evaluation of tumour staging 
based on the 8th edition of the AJCC cancer staging was 
performed. Disease-free survival (DFS), local recurrence-
free survival (LRFS), regional recurrence-free survival 
(RRFS), total follow-up and 5-year overall survival (OS) 
were registered.
Statistical analysis
To test for differences among groups, Fisher’s exact test 
was used for categorical data, while the Student’s t-test 
was used for continuous data. The role of each possible 
prognostic factor (univariate analysis) and their inde-
pendent effect (multivariate analysis) was explored us-
ing logistic regression model or Cox-proportional hazard 
model as appropriate. Survival analysis was performed by 
the Kaplan-Meier method. Probability values lower than 
0.05 were considered statistically significant. All analyses 
were performed with STATA 12.1 software (Stata Corp., 
College Station, TX, USA).
Results
Since 2008, our institution has used TORS mainly to re-
sect hypertrophic bases of tongue (BOT) in case of sleep 
apnoea disorders and surgically resectable OPSCC. Up to 
December 2017, 514 TORS procedure were executed. In 
the same period, a total of 60 OPSCC were treated with 
TORS alone or in combination with adjuvant RT or CRT 
based on pathologic cancer staging. 
All patients were treated with intent-to-cure. Management 
strategies included surgery alone in 30% (18/60), TORS-
RT in 33.3% (20/60) and TORS-CRT in 36.7% (22/60). 
Patients undergoing TORS-CRT were more likely to have 
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higher nodal, ECS and overall AJCC stages (p < 0.001). 
The primary tumour was classified as cT1(22/60; 36.7%), 
cT2(23/60; 38.3%), cT3(6/60; 10%) and cTx(9/60; 15%). 
The primary tumour arose in the BOT in 25 patients 
(41.7%), tonsils in 28 patients (46.7%), soft palate in 2 
(3.3%) and posterior pharyngeal wall in 3 (5%). Unfor-
tunately in 2 cTx, the primary was not found, while the 
primary was in the palatine tonsil or in the BOT in 3 and 
4 cases, respectively (all pT1). Regarding HPV status, 33 
(61.1%) were considered HPV-positive.
In all patients, frozen section margins were obtained to 
check for clear margins. Margins remained clear in 56.7% 
of patients on final pathology. Of the remaining 26 pa-
tients 4 had only positive lateral margin, while 4 had only 
positive deep margin. Only close lateral margin was found 
in 5 cases, while 6 had only close deep margin and 3 pa-
tients had close both deep and lateral margins. In all, pa-
tients with at least one positive margin were 12 (20%) and 
those with close margins were 14 (23.3%).
The pathological staging according the 7th edition AJCC 
is shown in Table I. The re-evaluation according 8th AJCC 
is displayed in Table II for HPV-/p16-OPSCC and in Ta-
ble III for HPV-related OPSCC. The secondary intention 
healing was the predominant choice in simple and no-ex-
tensive resection’s cases (90%; 54/60). One facial artery 
myo-mucosal (FAMM) and 1 buccinator-based myomu-
cosal (BMM) flaps were used to cover extensive carotid 
exposure in two patients with a tonsillar cancer (T2). The 
temporalis myofascial flap (TMF) was adopted to restore 
a competent velopharyngeal sphincter and a watertight 
seal between the pharynx and neck in a case of OPSCC in-
volving part of soft palate and the anterior tonsillar pillar 
(T2). In 3 cases with extensive tumour of BOT involving 
tonsil and soft palate (T3), the surgical defect was recon-
structed with an antero-lateral thigh (ALT) free flap. 
Concurrent neck dissection was performed in 26 patients 
(43.3%). In 15 (25%) cases with high probability of fis-
tula, a staged neck dissection was done after a mean of 
27.7 ± 13.4 days (range 8-60). In 7 patients (11.7%), the 
neck dissection was previously done (-28.1 ± 11.5 days; 
range -41 to -12) because of the high risk of vascular inju-
ry or because the patient was referred to our institution for 
a primary tumour (unknown cases). The extent of dissec-
tion most commonly included levels IIa, IIb, III and IV. 
The ECS was noted in 24% of neck dissections, and the 
rate decreased in HPV-related OPSCC (21.4%). 
Patients undergoing TORS-RT received a mean dose 
of 57  ±  5.6 Gy on T (range 50-66 Gy) and a mean of 
51.4 ± 15.4 on N (range 0-60). In the TORS-CRT group, a 
mean dose of 59.7 ± 4.2 Gy of radiation was delivered on 
T, ranging from 54 to 66, and a mean dose of 59 ± 3.1 on 
N (range 54-66). Further, TORS-CRT group most com-
monly received a mean dose of 254.5 ± 46 mg/m2 cispl-
atin (range 180-300). 
The mean duration of follow-up for the 60 patients was 
30.3 ± 26.9 months. The 5-year OS rate of the total group 
was 77.6%, in case of HPV-related OPSCC the 5-year 
OS increased to rate of 88.2%. The 5-year DFS rate was 
85.2% (HPV+ group  =  93.6%); the 5-year LRFS rate 
90.6% (HPV+ group  =  96.8%) and 5-year RRFS was 
87.4% (HPV+ group = 93.6%). 
Figure 1 shows the different survivals by HPV infection.
Data for the univariate and multivariate Cox regres-
sion model are shown in Table  IV. Of note, at univari-
ate analysis positive margins were predictive of regional 
relapses while HPV-related cancers were related to bet-
ter OS. However, the statistical significance was lost in 
multivariate analysis for both factors. On the contrary, 
at multivariate analysis, tonsillar and BOT cancers were 
Table I. Clinical TNM classification 7th ed.
cN (%)
cT N0 N1 N2a N2b N2c Total
Tx 0 1 (6.7) 3 (60) 4 (36.4) 1 (50) 9 (15)
T1 13 (48.2) 5 (33.3) 1 (20) 3 (27,3) 0 22 (36.7)
T2 11 (40.7) 8 (53.3) 1 (20) 3 (27.3) 0 23 (38.3) 
T3 3 (11.1) 1 (6.7) 0 1 (9.1) 1 (50) 6 (10)
Total 27 15 5 11 2 60 
Table II. New pathological TNM classification 8th ed. in HPV-/p16- OPSCC.
pN (%)
pT N0 N1 N2a N2b N2c N3b Total
T0 0 1 (20) 0 0 0 0 1 (4.8)
T1 2 (33.3) 1 (20) 1 1 (50) 0 1 (16.7) 6 (29.6)
T2 3 (50) 3 (60%) 0 1 (50%) 1 (100) 3 (50) 11 
(52.4)
T3 1 (16.7) 0 0 0 0 2 (33.3) 3 (14.3)
Total 6 5 1 2 1 6 21 
Table III. New pathological TNM classification 8th ed. in HPV+/p16+ OPSCC.
pN (%)
pT N0 N1 N2 Total
T0 0 1 (6.3) 0 1 (3.6)
T1 4 (40) 8 (50) 1 (50) 13 (46.4)
T2 4 (40) 6 (37.5) 1(50) 11 (39.3)
T3 2 (20) 1 (6.25) 0 3 (10.7)
Total 10 16 2 28 
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significantly related with a high risk of neck recur-
rence, but should be considered a bias. In fact, 53 of 60 
(88.3%) patients were palatine tonsil or BOT cancers; 
hence, if only both sites were considered, any statistical 
significance not correlating the site to any risk of neck 
recurrence was lost (HR = 6.1, p = 0.27, 95% CI = 0.24-
156.06).
Regarding complications, we did not register any major or 
life-threatening intra-operative complications. Only one 
patient, who had concurrent neck dissection, experienced 
post-operative bleeding into the neck. Eight (13.3%) pa-
tients had post-operative bleeding from primary tumour 
resection field; 5 patients from tonsil and 3 from BOT. 
Oral bleeding had a mean of 6.2 ± 3.7 days. No total local 
or free flap failure were registered; whilst a partial necro-
sis of TMF that did not affect the healing and two flap 
dehiscences (1 FAMM and 1 ALT) that needed a surgical 
revision were recorded. Only the same ALT patient with 
flap dehiscence experienced pharyngocutaneous fistula 
that was treated with both surgical revision and compres-
sive dressings. Tracheostomy was performed routinely in 
the first series of patients (15 cases until 2012). As our 
experience increased, tracheostomy was reserved only 
in difficult intubation cases, cT3 tumours, or cases who 
needed reconstruction with free flaps or local bulky flaps. 
The mean duration of tracheostomy use was 7.4  ±  2.6 
days, and nasogastric tube 14.3 ± 6.9 days. Only one pa-
tient (pT3N2b of BOT invading tonsil and soft palate with 
ALT reconstruction) experienced a post-operative severe 
dysphagia, needing a permanent tracheostomy tube and 
percutaneous endoscopic gastrostomy (PEG) feeding.
Discussion
TORS is a fascinating new tool that is useful in the mod-
ern management of selected cases of OPSCC. In a sys-
tematic review of surgical and nonoperative therapy data 
for oropharyngeal SCC, Yeh et al. 6 found that TORS can 
achieve oncologic outcomes that compare favourably to 
primary RT, with an improved toxicity profile. In that re-
view, TORS-based therapy OS was reported to range from 
81%-100% and DFS from 85.7%-96%. Recently, Moore 
et al. 7 reported excellent outcomes with a 1, 3 and 5-year 
OS rate of 98%, 91% and 86%, DFS of 99%, 96% and 
94%, and a local or regional disease-free survival rate 
of 95%, 93%, and 92%. Furthermore, Mahmoud et al.  8 
demonstrated that 3-year survival was superior in patients 
undergoing TORS versus non-surgically treated patients 
(93% vs 83%, p < 0.001), although patients with HPV-
positive disease showed no significant difference in sur-
Fig. 1. A) Local Recurrence-Free Survival; B) Regional Recurrence-Free Survival; C) Distant Metastasis-Free Survival; D) Overall Survival.
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vival by treatment modality (p = 0.116), while the 3 year-
survival advantage of TORS over definitive radiotherapy 
was only evident in the HPV-negative cohort (83% vs 
66%, p = 0.2). Our data support these excellent outcomes 
as the 5-year DFS rate of 85.2% increased to 93.6% in 
case of HPV-related OPSCC, and a 5-year OS rate of 
77.6% (HPV+ group = 88.2%).
An important consideration should be made about surgi-
Table IV. 
Univariate and multivariate Cox regression model for local relapses
Univariate Multivariate
HR P value 95% CI HR P value 95% CI
Age 0.60 0.58 0.1-3.6 0.75 0.84 0.5-11.22
Tumour site 0.67 0.53 0.19-2.31 1.38 0.81 0.11-17.92
pT 1 1 0.3-3.25 2.39 0.36 0.37-15.31
pN 1.9 0.2 0.71-5 1.6 0.39 0.55-4.62
Margins 2 0.16 0.76-5.28 1.96 0.39 0.42-9.19
HPV 0.25 0.26 0.02-2.81 0.08 0.23 0.01-4.85
Univariate and multivariate Cox regression model for regional relapses
Univariate Multivariate
HR P value 95% CI HR P value 95% CI
Age 0.7 0.63 0.15-3.08 2.17 0.59 0.13-37.42
Tumour site 1.3 0.5 0.6-2.83 6.05 0.03 1.16-31.56
pT 1.54 0.39 0.57-4.17 16.2 0.11 0.53-493
pN 1.5 0.34 0.67-3.12 1.96 0.28 0.58-6.6
Margins 2.7 0.03 1.1-6.7 3 0.27 0.42-21.36
HPV 0.36 0.27 0.06-2.19 0.97 0.986 0.05-20.4
Univariate and multivariate Cox regression model for disease-free survival
Univariate Multivariate
HR P value 95% CI HR P value 95% CI
Age 0.92 0.9 0.23-3.66 2.83 0.35 0.32-24.9
Tumour site 1.15 0.71 0.54-2.47 2.93 0.13 0.73-11.85
pT  1.27 0.6 0.5-3.2 2.7 0.24 0.5-14.47
pN 1.65 0.17 0.81-3.32 2.27 0.11 0.83-6.19
Margins 2.14 0.06 0.98-4.67 1.59 0.45 0.48-5.27
HPV 0.27 0.14 0.05-1.51 0.43 0.51 0.03-5.28
Univariate and multivariate Cox regression model for overall survival
Univariate Multivariate
HR P value 95% CI HR P value 95% CI
Age 0.99 0.98 0.34-2.86 0.28 0.24 0.32-2.38
Tumour site 1.39 0.24 0.8-2.42 1.92 0.37 0.47-7.9
pT 1 0.99 0.44 2.28 1.57 0.68 0.18-13.88
pN  1.11 0.68 0.67-1.85 0.95 0.94 0.26-3.44
Margins 1.3 0.33 0.74-2.39 1.94 0.23 0.66-5.71
HPV 0.24 0.02 0.07-0.79 0.23 0.16 0.03-1.81
Neck Dissection 0.8 0.65 0.3-2.14 0.6 0.56 0.11-3.26
ECS 2.23 0.23 0.6-8.36 8.8 0.22 0.27-292.66
Radiotherapy 0.7 0.56 0.22- 2.25 1.24 0.86 13.6
Chemotherapy 0.21 0.13 0.03-1.6 0.03 0.164 0-3.9
HR: hazard ratio; 95% CI: confidence interval; ECS: Extra-capsular spread.
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cal margins in TORS for OPSCC. No universal definition 
of what constitutes an inadequate resection margin exists 
yet 9. The guidelines from the American Society of Clinical 
Oncology (ASCO), National Comprehensive Cancer Net-
work (NCCN) and European Oncology Institute (IEO) all 
define a close margin as 5 mm or less without any subsite 
distinction. A published survey of members of the Ameri-
can Head and Neck Society, regarding the definition of 
margins, revealed that the most common cutoff for a clear 
margin was greater than 5 mm on microscopic examina-
tion  10. Alicandri-Ciufelli et al.  11, in their comprehensive 
review on surgical margins in the head and neck, reported 
that most studies use a margin distance of 5 mm or greater 
to define margin clearance, with the exception of glottic 
cancer in which there is long-standing consensus that re-
section margins may be as limited as 1 to 2 mm and still be 
considered adequate. For TORS resection of oropharyngeal 
tumours, Weinstein et al. 12 defined a margin of 2 mm or less 
to be considered close and those greater than 2 mm consid-
ered a free margin, which has been adopted at the authors’ 
institution. Obviously, the positive margin rate after TORS 
for OPSCC widely varies in the literature (2-26%) 8 13. In 
our study, we stated that clear margin was > 5 mm on mi-
croscopic evaluation, and thus we obtained 23.3% close 
margins and 20% positive margins. 
This relative high positive margin rate, compared to out-
comes at other institutions, might be affected by several 
factors. Our series also included all patients since the be-
ginning of our robotic experience as well as T3 tumours 
that are not usually included in most published series. It 
is well known that the rate of clear margins increases with 
surgical experience; nevertheless, it is crucial to note that 
the experience of our pathologists in reporting clear mar-
gins increased with the workload over time. In fact, no 
dedicated head-neck pathologists are present in our insti-
tution. Furthermore, our hospital can be considered as a 
low volume centre. This issue is clearly evident in the lit-
erature. Cracchiolo et al. 13 reported that the incidence of 
positive margins was higher in lower volume than higher 
volume hospitals, but improves over time. 
On the other hand, other authors have failed to find surgi-
cal margin status as a significant prognostic factor in head 
and neck cancer 14-17. Reasons for failing to find a signifi-
cant impact for margin status include other variables that 
have a greater impact on prognosis than margins, such 
as limitations in standard histopathology for assessment 
of margin status field cancerisation and effect of post-
operative RT in negating the adverse impact of positive 
margins. In addition, technical issues during surgery, such 
as tearing of the specimen, tissue retraction, or shrinkage 
cautery effect around tumour margins may lead to close 
or positive margins on the pathology report, despite com-
plete tumour resection. However, Molony et al. 18 showed 
that margin status had no impact on disease specific sur-
vival in patients with p16-positive disease. Similarly, Iyer 
et al. 19 reported that margin status predicted poorer sur-
vival in p16-negative patients, but not among patients who 
were p16- positive. Moreover, Kaczmar et al. 20 reported 
that margins < 2 mm did not lead to increased recurrence 
compared with margins > 2 mm in patients undergoing 
TORS. Regarding the survival, another study did not 
demonstrate any significant changes even after exclud-
ing TORS-treated patients with HPV-related OPSCC with 
positive surgical margins from 3-year survival analyses 8.
Usually tracheostomy is avoided in most (70-100%) cas-
es, regardless of the use of adjuvant therapy 21, especially 
in early OPSCC even in case of local flap reconstruction. 
At many centres, tracheostomy was performed initially at 
the time of TORS in anticipation of airway oedema during 
the perioperative period; however, the majority of patients 
were decannulated within a few days. As the surgeons’ 
experience increased, many of the centres moved away 
from routine tracheostomy at the time of TORS. In our 
experience, tracheostomy was routinely performed at the 
beginnings and then reserved to patients with difficult ex-
posure or those with cT3 that needed regional or free flap 
reconstruction. 
Additionally, TORS is usually associated with low mor-
bidity rates and lower blood loss in comparison with open 
surgical procedures. These associated characteristics also 
reflect the shorter average hospital stays (4.2 days). The 
percutaneous endoscopic gastrostomy (PEG) dependen-
cy rate following TORS is 0-9.5% in 1 year and 0% in 2 
years 22 23. Another analysis of 177 patients from a mul-
ticentre study reported a long-term tracheostomy rate of 
2.3%, and a long-term gastrostomy tube rate of 5%. The 
average duration of tracheostomy use was 7 days, and na-
sogastric tube 12.5 days 23. Our study showed overlapping 
data. Amongst the TORS studies, the quality of life was 
investigated in only a few studies. Leonhardt et al. 23 dem-
onstrated a decline in the eating, diet and speech domains 
from baseline at 6 months in the postoperative course, but 
these scores improved to baseline levels for eating and 
diet by 12 months. Lee et al. 24 showed improved dyspha-
gia scores when comparing TORS to open surgery with 
mandibulotomy for patients with T1-T3 tonsil SCC. Dzi-
egielewski et al.  25 demonstrated a decline in all scores 
at 3 weeks after surgery, with the lowest scores observed 
at 3 months in the postoperative course. Speech attitude, 
aesthetic, social and overall scores eventually returned 
to baseline, but speech function and aesthetic scores had 
only partial recovery and remained below baseline scores 
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at 12 months. Two studies included a comparison of 
quality of life (QOL) outcomes between TORS and RT. 
More et al.  26 found that the preoperative and 3 month 
postoperative MD Anderson Dysphagia Index (MDADI) 
scores were similar between the two groups. However, by 
6 months and at the 12-month postoperative follow-up, 
patients treated with TORS and adjuvant therapy had sig-
nificantly better MDADI scores. Chen et al. 27 compared 
QOL scales between patients who underwent initial sur-
gical resection with either transoral laser microsurgery 
or TORS versus definitive CRT. At 1-year, there was no 
significant difference between the surgical group and the 
definitive chemoradiation group except for the swallow-
ing score, which was better in the surgical group.
In one of the largest prospective studies of patients undergo-
ing TORS 28, postoperative dysphagia improved significantly 
more quickly in the TORS-only group vs. patients who had 
adjuvant CRT. In summary, the TORS-only group had sig-
nificantly better scores than the TORS+CRT group in the dif-
ferent QOL questionnaires. Similarly, Sethia et al. 29 showed 
that patients who underwent TORS alone had continued 
improvement in QOL in multiple domains shortly after 
surgery. These TORS-alone patients reported higher QOL 
scores in eating at 3 and 6 months postsurgery compared to 
adjuvant RT or CRT. TORS alone and adjuvant RT reported 
less social disruption than adjuvant CRT at 3 months, and 
TORS alone had higher speech scores compared to adjuvant 
CRT at 3 months and adjuvant RT at 6 months. Adjuvant 
CRT had lower overall QOL scores compared to adjuvant 
RT or TORS alone at baseline and 3 months, adjuvant RT at 
3 weeks and TORS alone at 6 months. Although many pa-
tients in this study received PEG placement, it is important to 
note that the total number of patients with PEG dependence 
greatly diminished from 3 to 12 months. Thus, the majority 
of patients received PEG placement prophylactically as rec-
ommended by their radiation oncologist or as a direct result 
of dysphagia due to adjuvant therapy.
For what concerns surgical complications, fistula forma-
tion was noted in the series from the Mayo Clinic in 6% 
of cases. These patients underwent concurrent neck dis-
section at the time of TORS. In all four cases, the fistulae 
responded to treatment with daily packing and antibiot-
ics 21 30. Postoperative haemorrhage can be a life-threaten-
ing event in the case of TORS. The rate of postoperative 
haemorrhage varied 0% to 9% 31-35. Chia et al. 36 summa-
rised the common complications in a 2013 multi-institu-
tional survey of all TORS-trained surgeons in the United 
States. An electronic survey was sent to 300 TORS-trained 
surgeons. Forty-five surgeons responded to the survey and 
reported a postoperative haemorrhage rate of 3.1% requir-
ing readmission. There were a total of 6 deaths among 
2015 procedures (0.3%). Other complications included 
temporary hypoglossal nerve injury (0.9%), lingual nerve 
injury (0.6%) and tooth injury (1.4%).
For what concerns reconstructive options, the majority of 
robotic surgeons favour leaving the oropharyngeal defects 
to heal by secondary intention following TORS for early 
OPSCC (cT1-2). However, surgical resection inevitably 
affects the native function of the oropharynx; therefore 
our group advocates the use of NBI in order to obtain free 
margins and reduce over-resections, consequently mini-
mising the risk of functional impairments 4. Among exist-
ing classification schemes for oropharyngeal defects, the 
reconstructive algorithm developed by de Almeida et al. 37 
seems to be easier to apply in the robotic surgery frame-
work. In our experience, we satisfactorily used FAMM 
and BMM for class I/II defects 38. Additionally, in a case 
of class III defect our group successfully adopted the TMF 
(Fig. 2) to restore a competent velopharyngeal sphincter 
and a watertight seal between the pharynx and neck 39. In 
cases of class IV defects, we used the ALT harvested in a 
particular petal shape that allows one petal to replace the 
rear side of the palate, one for the front side of the palate 
and the tonsillar fossa and the third petal to reconstruct 
the BOT. Flap insetting is the most challenging phase due 
to severely restricted physical access and visualisation. 
However, in our experience the accurate shape and meas-
ure of the flap allow to thoroughly perform manual inset, 
although the robot might be used for suturing parts of flap 
in deeper and narrower spaces. 
From an economical point of view, comparing the cost of 
TORS to the cost of primary radiotherapy is more challeng-
ing. In a comparative study, de Almeida et al. 40 performed 
an extensive cost-analysis, comparing the cost of TORS 
versus that of primary RT for the management of early T-
classification oropharyngeal cancer. Their study accounted 
Fig. 2. Schematic illustration of the oropharyngeal resection suitable for 
reconstruction with the temporalis muscle flap. A) The dotted line shows the 
surgical resection of the area that includes part of the soft palate and the 
lateral pharyngeal wall; B) The surgical defect with internal carotid artery 
exposure; C) The temporalis muscle flap reconstruction covering the lateral 
pharyngeal wall and restoring the soft palate.
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for variations in adjuvant therapy, costs, utilities, complica-
tions and recurrence rates. TORS demonstrated a cost sav-
ings of $ 1,366. However, the cost-effectiveness of TORS is 
unlikely to be realised if used in an unselected fashion. This 
concept was demonstrated in three recent cost-effectiveness 
studies comparing TORS and radiotherapy for various pop-
ulations of OPSCC 40-42. The results of each study, although 
varied in their conclusions, demonstrate significant sensi-
tivity to the frequency of adjuvant therapy. This implies that 
the use of TORS in unselected patients who are likely to 
require adjuvant therapy is unlikely to be a cost-effective 
strategy. Thus, patient selection is the key to the useful ap-
plication of this modality. Furthermore, the recognition of 
OPSCC subgroups that would most likely benefit from 
TORS alone or with adjuvant treatments would be advis-
able in order to provide a significant treatment opportunity 
with fewer complications and better quality of life.
Conclusions
In selected patients TORS appears to yield similar onco-
logic outcomes and functional outcomes to traditional tech-
niques and non-operative treatment with a possible benefit 
on long-term quality of life. Our data demonstrate compa-
rable treatment outcomes to other published larger series. 
In our practice, TORS is easy and safe, and reconstruction 
with flaps might increase the surgical indications without 
compromising oncological and functional outcomes. 
The future offers exciting opportunities to combine TORS 
and radiotherapy in unique ways. However, further re-
search is needed to clarify the indications for and delivery 
of adjuvant therapy following TORS resections.
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